Financial News
Morgan Stanley double-upgrades Biogen and says the stock can surge another 30% (BIIB)
- Morgan Stanley on Monday upgraded Biogen from underweight to overweight — a rare double upgrade — citing compelling risk versus reward in the long-term.
- The firm also boosted its price target on Biogen to $357 from $263. The new target price represents a more than 30% upside from where Biogen traded at Friday's close.
- Shares of Biogen gained nearly 5% on Monday.
- Watch Biogen trade live on Markets Insider.
- Read more on Business Insider.
Biogen got a rare double upgrade on Monday from Morgan Stanley, which boosted its rating on the company to overweight from underweight citing compelling long-term risk versus reward.
Morgan Stanley also boosted its Biogen price target to $357 from $263. The new figure is more than 30% higher than Biogen's Friday closing price.
Shares of Biogen jumped nearly 5% during intraday trading Monday.
"In the near-term, we believe BIIB is likely to face 10%+ in downside pressure due to multiple at-risk generic launches for multiple sclerosis (MS) drug Tecfidera," analysts led by Matthew Harrison wrote Monday.
He continued: "However, we expect investors to quickly look past the Tecfidera downside and start to price in higher odds of success for aducanumab, Biogen's investigational drug which is the first potential disease-modifying therapy for Alzheimer's disease."
Morgan Stanley said that it believes investors are currently pricing in a less than 25% probability of success, but that will increase to at least 50% as the drug moves closer to its potential FDA approval date, expected in March 2021.
Investors who take a "wait-and-see approach" could miss a potential up to 20% move in the near term for Biogen, according to the note.
"While BIIB remains a high-risk/ high-reward stock, we think now is the right time to take the risk," said Harrison.
Biogen has shed roughly 5% year-to-date.
NOW WATCH: Why you don't see brilliantly blue fireworks
See Also:
- I don't go anywhere without my Soludos espadrilles in the summer — I've bought the same pair 5 times
- The Beverly Hills estate that Jennifer Aniston and Brad Pitt spent 3 years renovating isn't selling. Look inside the $44.5 million home that's been on the market for over a year.
- What 6 of Wall Street's biggest firms are saying about the election's implications for unusually tense investors — and their strategies for gains no matter the results
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.